Treatment of autoimmune disease using tolerization in combinatio

Details Treatment of autoimmune disease using tolerization in combinatio Treatment of autoimmune disease using tolerization in combinatio

1998-01-23

1999-08-10

Saunders, David

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

424810, 514 2, 514 3, 514 4, 514 21, 514826, 514866, 514885, 514903, 514253, A61K 3900, A61K 3817, A61K 3828, A61K 3800

Patent

active

059355778

ABSTRACT:
A combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease. The amounts of bystander antigen and methotrexate are effective in combination to suppress autoimmune response associated with the autoimmune disease

REFERENCES:
patent: 5399347 (1995-03-01), Trentham et al.
patent: 5571499 (1996-11-01), Hafler et al.
patent: 5571500 (1996-11-01), Hafler et al.
patent: 5641474 (1997-06-01), Hafler et al.
patent: 5645820 (1997-07-01), Hafler et al.
patent: 5720955 (1998-02-01), Weiner et al.
patent: 5783188 (1998-07-01), Weiner et al.
patent: 5843445 (1998-12-01), Weiner et al.
patent: 5856446 (1999-01-01), Weiner et al.
Trentham, D.E. et al. Science 261:1727-1730, Sep. 1993.
Barnett, M.L. et al. Arthritis & Rheumatism 39(4):623-628, Apr. 1996.

Affiliated with

Also associated with

Rating

Treatment of autoimmune disease using tolerization in combinatio does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of autoimmune disease using tolerization in combinatio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of autoimmune disease using tolerization in combinatio will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1117583